Filgotinib + Placebo to match filgotinib + Prednisone
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Noninfectious Uveitis
Conditions
Noninfectious Uveitis
Trial Timeline
Jul 26, 2017 → Apr 22, 2021
NCT ID
NCT03207815About Filgotinib + Placebo to match filgotinib + Prednisone
Filgotinib + Placebo to match filgotinib + Prednisone is a phase 2 stage product being developed by Gilead Sciences for Noninfectious Uveitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT03207815. Target conditions include Noninfectious Uveitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03207815 | Phase 2 | Terminated |
Competing Products
2 competing products in Noninfectious Uveitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| FTY720 + Oral Corticosteroid | Novartis | Phase 2 | 52 |
| REGN7041 | Regeneron Pharmaceuticals | Phase 1/2 | 40 |